Quarterly infographic: MRSA, MSSA and Gram-negative bacteraemia and CDI, data up to July to September 2024
Updated 23 January 2025
Applies to England
Gram-negative bacteraemias (E. coli, Klebsiella spp. and P. aeruginosa)
Pseudomonas aeruginosa (P. aeruginosa) bacteraemia
July to September 2023: 8 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
July to September 2024: 9 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
Klebsiella species (Klebsiella spp.) bacteraemia
July to September 2023: 24 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
July to September 2024: 25 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
Escherichia coli (E. coli) bacteraemia
July to September 2023: 77 out of every 100,000 persons developed an E. coli bacteraemia.
July to September 2024: 79 out of every 100,000 persons developed an E. coli bacteraemia.
Staphylococcus aureus (S. aureus) MRSA and MSSA bacteraemia and Clostridioides difficile (C. difficile) infections
Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia
July to September 2023: 1.4 out of every 100,000 persons developed an MRSA bacteraemia.
July to September 2024: 1.8 out of every 100,000 persons developed an MRSA bacteraemia.
Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia
July to September 2023: 23 out of every 100,000 persons developed an MSSA bacteraemia.
July to September 2024: 24 out of every 100,000 persons developed an MSSA bacteraemia.
Clostridioides difficile (C. difficile) infection
July to September 2023: 30 out of every 100,000 persons developed a C. difficile infection.
July to September 2024: 37 out of every 100,000 persons developed a C. difficile infection.